From: New strategy for testing efficacy of immunotherapeutic compounds for diabetes in vitro
Treatment | Percent of cell phenotypes | ||
---|---|---|---|
 | CD4+CD3+ | CD4+CD25hi | CD11b+CD86+ |
Medium | 24.5 ± 8.2 | 0.5 ± 0.2 | 31.8 ± 7.1 |
Insulin | 34.4 ± 3.8 | 1.2 ± 0.6 | 44.8 ± 8.6 |
Insulin + DNAhsp65 | 49.2 ± 6.8a | 6.7 ± 1.6b | 77.6 ± 5.1b |
Insulin + Hsp65 | 42.8 ± 4.5a | 9.6 ± 3.7b | 69.3 ± 6.0b |
Insulin + Hsp70 | 43.1 ± 3.9a | 7.7 ± 1.7b | 65.0 ± 7.4b |